《AComparisonofRE-LYandROCKETAFTrialDesignsand》.pptVIP

A Comparison of RE-LY and ROCKET AFTrial Designs and Outcomes C. Michael Gibson, M.S., MD. RE-LY: Study Design Atrial fibrillation ≥1 Risk Factor Absence of contra-indications 951 centers in 44 countries R Warfarin adjusted (INR 2.0-3.0) N=6000 Dabigatran Etexilate 110 mg BID N=6000 Dabigatran Etexilate 150 mg BID N=6000 Blinded Event Adjudication. Open Blinded Patients were eligible if they had atrial fibrillation documented on electrocardiography performed at screening or within 6 months beforehand and at least one of the following characteristics: Previous stroke or transient ischem